BIIB Key Statistics, Chart & Performance
The current stock price of BIIB is 177.55 USD. In the past month the price increased by 11.27%. In the past year, price increased by 18.34%.
BIIB Latest News, Press Relases and Analysis
BIIB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.83 | 397.98B | ||
| AMGN | AMGEN INC | 14.42 | 169.83B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.61 | 112.81B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.13 | 76.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 793.06 | 53.43B | ||
| INSM | INSMED INC | N/A | 40.49B | ||
| NTRA | NATERA INC | N/A | 32.17B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.37 | 20.88B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B | ||
| INCY | INCYTE CORP | 14.82 | 18.68B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 37.23 | 15.52B |
Related stock screener links
About BIIB
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Company Info
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Michel Vounatsos
Employees: 7605
Phone: 17814642000
BIOGEN INC / BIIB FAQ
Can you describe the business of BIOGEN INC?
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
What is the current price of BIIB stock?
The current stock price of BIIB is 177.55 USD. The price increased by 0.97% in the last trading session.
Does BIOGEN INC pay dividends?
BIIB does not pay a dividend.
What is the ChartMill technical and fundamental rating of BIIB stock?
BIIB has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is BIOGEN INC (BIIB) stock traded?
BIIB stock is listed on the Nasdaq exchange.
What is the Short Interest ratio of BIOGEN INC (BIIB) stock?
The outstanding short interest for BIOGEN INC (BIIB) is 4.19% of its float.
BIIB Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BIIB. When comparing the yearly performance of all stocks, BIIB is one of the better performing stocks in the market, outperforming 84.35% of all stocks.
BIIB Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BIIB. Both the health and profitability get an excellent rating, making BIIB a very profitable company, without any liquidiy or solvency issues.
BIIB Financial Highlights
Over the last trailing twelve months BIIB reported a non-GAAP Earnings per Share(EPS) of 16.74. The EPS increased by 2.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.98% | ||
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| Debt/Equity | 0.35 |
BIIB Forecast & Estimates
42 analysts have analysed BIIB and the average price target is 181.47 USD. This implies a price increase of 2.21% is expected in the next year compared to the current price of 177.55.
For the next year, analysts expect an EPS growth of -7.79% and a revenue growth 1.98% for BIIB